BR112012011980A2 - Métodos de produzir células transformadas de yarrowia lipolytica e proteínas-alvocompreendendo n-glicanos, células transformadas de yarrowia lipolytica e suas culturas, bem como composição compreendendo glicoproteínas - Google Patents
Métodos de produzir células transformadas de yarrowia lipolytica e proteínas-alvocompreendendo n-glicanos, células transformadas de yarrowia lipolytica e suas culturas, bem como composição compreendendo glicoproteínas Download PDFInfo
- Publication number
- BR112012011980A2 BR112012011980A2 BR112012011980-0A BR112012011980A BR112012011980A2 BR 112012011980 A2 BR112012011980 A2 BR 112012011980A2 BR 112012011980 A BR112012011980 A BR 112012011980A BR 112012011980 A2 BR112012011980 A2 BR 112012011980A2
- Authority
- BR
- Brazil
- Prior art keywords
- cell
- nucleic acid
- glycans
- transferase
- glcnac
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 67
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 67
- 238000000034 method Methods 0.000 title claims abstract description 39
- 241000235015 Yarrowia lipolytica Species 0.000 title claims abstract description 16
- 102000003886 Glycoproteins Human genes 0.000 title claims abstract description 15
- 108090000288 Glycoproteins Proteins 0.000 title claims abstract description 15
- 230000002538 fungal effect Effects 0.000 claims abstract description 10
- 210000004027 cell Anatomy 0.000 claims description 88
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims 55
- 102000039446 nucleic acids Human genes 0.000 claims 55
- 150000007523 nucleic acids Chemical class 0.000 claims 55
- 108060003306 Galactosyltransferase Proteins 0.000 claims 27
- 102000030902 Galactosyltransferase Human genes 0.000 claims 27
- 230000008685 targeting Effects 0.000 claims 27
- 108010070113 alpha-1,3-mannosyl-glycoprotein beta-1,2-N-acetylglucosaminyltransferase I Proteins 0.000 claims 23
- 101000918297 Caenorhabditis elegans Exostosin-2 homolog Proteins 0.000 claims 19
- 239000002773 nucleotide Substances 0.000 claims 16
- 125000003729 nucleotide group Chemical group 0.000 claims 16
- 102100021771 Endoplasmic reticulum mannosyl-oligosaccharide 1,2-alpha-mannosidase Human genes 0.000 claims 14
- 108010009689 mannosyl-oligosaccharide 1,2-alpha-mannosidase Proteins 0.000 claims 14
- 108010083819 mannosyl-oligosaccharide 1,3 - 1,6-alpha-mannosidase Proteins 0.000 claims 13
- GRHWEVYJIHXESA-HBHDJDHDSA-N beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)-[beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-beta-D-GlcpNAc Chemical compound O[C@@H]1[C@@H](NC(=O)C)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@H]3[C@@H]([C@@H](O)[C@H](O[C@H]4[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O4)O)[C@@H](CO)O3)NC(C)=O)[C@H](O)[C@@H](CO[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@H]3[C@@H]([C@@H](O)[C@H](O[C@H]4[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O4)O)[C@@H](CO)O3)NC(C)=O)O2)O)[C@@H](CO)O1 GRHWEVYJIHXESA-HBHDJDHDSA-N 0.000 claims 12
- 230000002950 deficient Effects 0.000 claims 12
- 230000000694 effects Effects 0.000 claims 12
- 210000002288 golgi apparatus Anatomy 0.000 claims 10
- 230000003834 intracellular effect Effects 0.000 claims 10
- WYUKJASPBYYQRJ-VSJOFRJTSA-N beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)-[beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-GlcpNAc-(1->4)-beta-D-GlcpNAc Chemical compound O[C@@H]1[C@@H](NC(=O)C)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)NC(C)=O)[C@H](O)[C@@H](CO[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)NC(C)=O)O2)O)[C@@H](CO)O1 WYUKJASPBYYQRJ-VSJOFRJTSA-N 0.000 claims 9
- 102000005744 Glycoside Hydrolases Human genes 0.000 claims 8
- 108010031186 Glycoside Hydrolases Proteins 0.000 claims 8
- 101150061302 och1 gene Proteins 0.000 claims 8
- 102100039059 Dol-P-Man:Man(5)GlcNAc(2)-PP-Dol alpha-1,3-mannosyltransferase Human genes 0.000 claims 4
- 101000958975 Homo sapiens Dol-P-Man:Man(5)GlcNAc(2)-PP-Dol alpha-1,3-mannosyltransferase Proteins 0.000 claims 4
- ZTOKCBJDEGPICW-UHFFFAOYSA-N Man3GlcNAc2 Natural products OC1C(NC(=O)C)C(O)OC(CO)C1OC1C(NC(C)=O)C(O)C(OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(COC3C(C(O)C(O)C(CO)O3)O)O2)O)C(CO)O1 ZTOKCBJDEGPICW-UHFFFAOYSA-N 0.000 claims 4
- ZTOKCBJDEGPICW-GWPISINRSA-N alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-beta-D-GlcpNAc Chemical compound O[C@@H]1[C@@H](NC(=O)C)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)O2)O)[C@@H](CO)O1 ZTOKCBJDEGPICW-GWPISINRSA-N 0.000 claims 4
- 210000002472 endoplasmic reticulum Anatomy 0.000 claims 4
- 102000003951 Erythropoietin Human genes 0.000 claims 3
- 108090000394 Erythropoietin Proteins 0.000 claims 3
- 102000009109 Fc receptors Human genes 0.000 claims 3
- 108010087819 Fc receptors Proteins 0.000 claims 3
- 102000051366 Glycosyltransferases Human genes 0.000 claims 3
- 108700023372 Glycosyltransferases Proteins 0.000 claims 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 3
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 3
- 102000003996 Interferon-beta Human genes 0.000 claims 3
- 108090000467 Interferon-beta Proteins 0.000 claims 3
- 102000008070 Interferon-gamma Human genes 0.000 claims 3
- 108010074328 Interferon-gamma Proteins 0.000 claims 3
- 229940105423 erythropoietin Drugs 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 229960003130 interferon gamma Drugs 0.000 claims 3
- 229960001388 interferon-beta Drugs 0.000 claims 3
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 3
- INOZZBHURUDQQR-AJNGGQMLSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]-4-methylpentanoic acid Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC1=CN=CN1 INOZZBHURUDQQR-AJNGGQMLSA-N 0.000 claims 2
- 102100032086 Dolichyl pyrophosphate Man9GlcNAc2 alpha-1,3-glucosyltransferase Human genes 0.000 claims 2
- 101000776319 Homo sapiens Dolichyl pyrophosphate Man9GlcNAc2 alpha-1,3-glucosyltransferase Proteins 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 108010022308 beta-1,4-galactosyltransferase I Proteins 0.000 claims 2
- 230000003197 catalytic effect Effects 0.000 claims 2
- 230000001413 cellular effect Effects 0.000 claims 2
- 230000004927 fusion Effects 0.000 claims 2
- 108010041601 histidyl-aspartyl-glutamyl-leucine Proteins 0.000 claims 2
- 102000035118 modified proteins Human genes 0.000 claims 2
- 108091005573 modified proteins Proteins 0.000 claims 2
- HNQXDLYBFNWFEE-VHZSLYHRSA-N n-[(2r,3r,4r,5s,6r)-2-[(2r,3r,4s,5r)-2-acetamido-5-[(2r,3s,4s,5r,6r)-5-hydroxy-6-(hydroxymethyl)-3,4-bis[[(2r,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy]oxan-2-yl]oxy-1-oxo-4-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] Chemical compound O([C@H]([C@H](C=O)NC(=O)C)[C@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H](CO[C@@H]1[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@@H]1[C@H]([C@@H](O[C@@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O[C@@H]1[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O HNQXDLYBFNWFEE-VHZSLYHRSA-N 0.000 claims 2
- 229940096437 Protein S Drugs 0.000 claims 1
- 241000235013 Yarrowia Species 0.000 claims 1
- 230000013595 glycosylation Effects 0.000 abstract description 4
- 238000006206 glycosylation reaction Methods 0.000 abstract description 4
- 239000000543 intermediate Substances 0.000 abstract description 2
- 230000037361 pathway Effects 0.000 abstract description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011143 downstream manufacturing Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 150000004676 glycans Chemical group 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1051—Hexosyltransferases (2.4.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/02—Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion
- C12N15/04—Fungi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2477—Hemicellulases not provided in a preceding group
- C12N9/2488—Mannanases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/58—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi
- C12N9/60—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi from yeast
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/01—Hexosyltransferases (2.4.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/01—Hexosyltransferases (2.4.1)
- C12Y204/01133—Xylosylprotein 4-beta-galactosyltransferase (2.4.1.133)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01024—Alpha-mannosidase (3.2.1.24)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01084—Glucan 1,3-alpha-glucosidase (3.2.1.84), i.e. mutanase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01114—Mannosyl-oligosaccharide 1,3-1,6-alpha-mannosidase (3.2.1.114)
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cell Biology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26282809P | 2009-11-19 | 2009-11-19 | |
| US61/262,828 | 2009-11-19 | ||
| PCT/IB2010/003154 WO2011061629A2 (en) | 2009-11-19 | 2010-11-19 | Yeast strains producing mammalian-like complex n-glycans |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112012011980A2 true BR112012011980A2 (pt) | 2021-09-08 |
Family
ID=44060124
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012011980-0A BR112012011980A2 (pt) | 2009-11-19 | 2010-11-19 | Métodos de produzir células transformadas de yarrowia lipolytica e proteínas-alvocompreendendo n-glicanos, células transformadas de yarrowia lipolytica e suas culturas, bem como composição compreendendo glicoproteínas |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20130053550A1 (enExample) |
| EP (1) | EP2501805B1 (enExample) |
| JP (1) | JP2013511272A (enExample) |
| KR (1) | KR20130055555A (enExample) |
| CN (1) | CN102834509A (enExample) |
| BR (1) | BR112012011980A2 (enExample) |
| CA (1) | CA2781240A1 (enExample) |
| DK (1) | DK2501805T3 (enExample) |
| WO (1) | WO2011061629A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2508613A3 (en) | 2007-04-03 | 2012-11-28 | Oxyrane UK Limited | Glycosylation of molecules |
| JP5990102B2 (ja) | 2009-09-29 | 2016-09-07 | ユニフェルシテイト ヘント | ホスホ−６−マンノースへのマンノース−１−ホスホ−６−マンノース結合の加水分解 |
| BR112012011980A2 (pt) | 2009-11-19 | 2021-09-08 | Oxyrane Uk Limited | Métodos de produzir células transformadas de yarrowia lipolytica e proteínas-alvocompreendendo n-glicanos, células transformadas de yarrowia lipolytica e suas culturas, bem como composição compreendendo glicoproteínas |
| SG189110A1 (en) | 2010-09-29 | 2013-05-31 | Oxyrane Uk Ltd | De-mannosylation of phosphorylated n-glycans |
| CA2812870C (en) | 2010-09-29 | 2020-06-09 | Oxyrane Uk Limited | Mannosidases capable of uncapping mannose-1-phospho-6-mannose linkages and demannosylating phosphorylated n-glycans and methods of facilitating mammalian cellular uptake of glycoproteins |
| SG11201403506TA (en) | 2011-12-30 | 2014-07-30 | Oxyrane Uk Ltd | Methods and materials for reducing degradation of recombinant proteins |
| BR112014016587A2 (pt) * | 2012-01-05 | 2020-10-27 | Novartis Ag | células fúngicas filamentosas deficientes de protease e métodos de uso das mesmas |
| CN104379162B (zh) | 2012-03-15 | 2017-03-15 | 奥克西雷恩英国有限公司 | 用于治疗蓬佩氏病的方法和材料 |
| PL2991683T3 (pl) | 2013-05-02 | 2020-03-31 | Glykos Finland Oy | Koniugaty glikoproteiny lub glikanu z toksycznym ładunkiem |
| EP3058083B1 (en) | 2013-10-14 | 2018-04-11 | SynAffix B.V. | Modified glycoprotein, protein-conjugate and process for the preparation thereof |
| AU2015218647B2 (en) | 2014-02-24 | 2021-10-21 | Ginkgo Bioworks, Inc. | Diacylglycerol acyl transferase (DGA1) polynucleotides, and methods of increasing yeast cell lipid production by overexpression of heterologous DGA1 |
| CA2954974A1 (en) | 2014-07-21 | 2016-01-28 | Glykos Finland Oy | Production of glycoproteins with mammalian-like n-glycans in filamentous fungi |
| US10941418B2 (en) * | 2016-05-03 | 2021-03-09 | Vib Vzw | Means and methods for generating complex glycans derived from fungal engineered hosts |
| WO2019204912A1 (en) | 2018-04-24 | 2019-10-31 | National Research Council Of Canada | Blood-brain barrier transmigrating therapeutic compounds and uses thereof |
| WO2020060948A1 (en) | 2018-09-17 | 2020-03-26 | Levadura Biotechnology, Inc. | Production of cannabinoids in yeast using a fatty acid feedstock |
| KR102167388B1 (ko) * | 2020-01-15 | 2020-10-19 | 코스맥스 주식회사 | 신규 로도스포리디움 토룰로이데스 균주 및 그 균주 배양액을 포함하는 화장료 조성물 |
| CN116042562B (zh) * | 2022-03-11 | 2023-10-20 | 山东恒鲁生物科技有限公司 | 重组酵母菌及其应用 |
Family Cites Families (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4307717A (en) | 1977-11-07 | 1981-12-29 | Lectec Corporation | Sterile improved bandage containing a medicament |
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| US4352883A (en) | 1979-03-28 | 1982-10-05 | Damon Corporation | Encapsulation of biological material |
| JPS5754588A (en) | 1980-09-19 | 1982-04-01 | Eiji Ichijima | Alpha-mannosidase |
| US4353888A (en) | 1980-12-23 | 1982-10-12 | Sefton Michael V | Encapsulation of live animal cells |
| US4407957A (en) | 1981-03-13 | 1983-10-04 | Damon Corporation | Reversible microencapsulation of a core material |
| US4837148A (en) | 1984-10-30 | 1989-06-06 | Phillips Petroleum Company | Autonomous replication sequences for yeast strains of the genus pichia |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| US4882279A (en) | 1985-10-25 | 1989-11-21 | Phillips Petroleum Company | Site selective genomic modification of yeast of the genus pichia |
| US4883666A (en) | 1987-04-29 | 1989-11-28 | Massachusetts Institute Of Technology | Controlled drug delivery system for treatment of neural disorders |
| US4929555A (en) | 1987-10-19 | 1990-05-29 | Phillips Petroleum Company | Pichia transformation |
| US5283187A (en) | 1987-11-17 | 1994-02-01 | Brown University Research Foundation | Cell culture-containing tubular capsule produced by co-extrusion |
| US5158881A (en) | 1987-11-17 | 1992-10-27 | Brown University Research Foundation | Method and system for encapsulating cells in a tubular extrudate in separate cell compartments |
| DE3829766A1 (de) | 1988-09-01 | 1990-03-22 | Akzo Gmbh | Verfahren zur herstellung von membranen |
| DE3829752A1 (de) | 1988-09-01 | 1990-03-22 | Akzo Gmbh | Integrale asymmetrische polyaethersulfonmembran, verfahren zur herstellung und verwendung zur ultrafiltration und mikrofiltration |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5084350A (en) | 1990-02-16 | 1992-01-28 | The Royal Institution For The Advance Of Learning (Mcgill University) | Method for encapsulating biologically active material including cells |
| US5272070A (en) | 1991-03-08 | 1993-12-21 | Board Of Regents, The University Of Texas System | Method for the preparation of cell lines producing Man3 GlcNac 2 asparagine-linked gylcans and cell lines produced thereby |
| DK0585368T3 (da) | 1991-04-25 | 1998-03-16 | Univ Brown Res Found | Implanterbart biokompatibelt immunisolatorisk vehikel til afgivelse af udvalgte terapeutiske produkter |
| US5968502A (en) | 1991-11-05 | 1999-10-19 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| US6042828A (en) | 1992-09-07 | 2000-03-28 | Kyowa Hakko Kogyo Co., Ltd. | Humanized antibodies to ganglioside GM2 |
| CA2169292C (en) | 1993-08-12 | 2010-11-23 | E. Edward Baetge | Improved compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules |
| US5589359A (en) | 1994-08-05 | 1996-12-31 | Chiron Corporation | Chimeric proteins |
| US5834251A (en) * | 1994-12-30 | 1998-11-10 | Alko Group Ltd. | Methods of modifying carbohydrate moieties |
| EP0922109A1 (en) | 1996-05-21 | 1999-06-16 | Novo Nordisk A/S | Novel yeast promoters suitable for expression cloning in yeast and heterologous expression of proteins in yeast |
| US6699658B1 (en) | 1996-05-31 | 2004-03-02 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
| US6300065B1 (en) | 1996-05-31 | 2001-10-09 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
| WO1998001473A1 (en) | 1996-07-05 | 1998-01-15 | Novo Nordisk A/S | Method for the production of precursors of insulin, precursors of insulin analogues, and insulin like peptides |
| CN1150313C (zh) | 1996-07-05 | 2004-05-19 | 诺沃挪第克公司 | 多肽的生产方法 |
| US6110703A (en) | 1996-07-05 | 2000-08-29 | Novo Nordisk A/S | Method for the production of polypeptides |
| DE69822453T2 (de) | 1997-04-23 | 2005-03-24 | Vlaams Interuniversitair Instituut Voor Biotechnologie | Regulationssystem für induzierbare expression von gene mit lambda-ähnlichen promotoren |
| US7442772B2 (en) | 1997-12-03 | 2008-10-28 | Genentech, Inc. | Antibodies to PRO361 polypeptide |
| WO1999037758A2 (en) | 1998-01-27 | 1999-07-29 | The Board Of Regents Of The University And Community College System Of Nevada On Behalf Of The University Of Nevada-Reno | Expression of proteolytically-sensitive peptides |
| WO2001042462A2 (en) | 1999-12-08 | 2001-06-14 | National University Of Singapore | Phospholipase a2 inhibitory peptides from python reticulatus |
| IL150314A0 (en) | 1999-12-30 | 2002-12-01 | Maxygen Aps | Improved lysosomal enzymes and lysosomal enzyme activators |
| US20020127219A1 (en) | 1999-12-30 | 2002-09-12 | Okkels Jens Sigurd | Lysosomal enzymes and lysosomal enzyme activators |
| DE60139467D1 (de) | 2000-05-17 | 2009-09-17 | Mitsubishi Tanabe Pharma Corp | Verfahren zur herstellung von proteinen unter reduktion von mannosephosphat in der zuckerkette und dadurch hergestelltes glykoprotein |
| US7795002B2 (en) * | 2000-06-28 | 2010-09-14 | Glycofi, Inc. | Production of galactosylated glycoproteins in lower eukaryotes |
| US7449308B2 (en) | 2000-06-28 | 2008-11-11 | Glycofi, Inc. | Combinatorial DNA library for producing modified N-glycans in lower eukaryotes |
| US7863020B2 (en) | 2000-06-28 | 2011-01-04 | Glycofi, Inc. | Production of sialylated N-glycans in lower eukaryotes |
| US7625756B2 (en) | 2000-06-28 | 2009-12-01 | GycoFi, Inc. | Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells |
| US8697394B2 (en) * | 2000-06-28 | 2014-04-15 | Glycofi, Inc. | Production of modified glycoproteins having multiple antennary structures |
| US7598055B2 (en) * | 2000-06-28 | 2009-10-06 | Glycofi, Inc. | N-acetylglucosaminyltransferase III expression in lower eukaryotes |
| KR100787073B1 (ko) | 2000-06-28 | 2007-12-21 | 글리코파이, 인크. | 변형된 당단백질의 제조방법 |
| EP2267135A3 (en) | 2000-06-30 | 2011-09-14 | Vib Vzw | Protein glycosylation modification in pichia pastoris |
| ES2258371B1 (es) | 2000-08-31 | 2007-05-16 | Dong Kook Pharmaceutical Co. Ltd. | Levadura transformante productora de hormona paratiroidea humana y procedimiento para producir la hormona. |
| US7001994B2 (en) | 2001-01-18 | 2006-02-21 | Genzyme Corporation | Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins |
| JP4774496B2 (ja) | 2001-06-14 | 2011-09-14 | 独立行政法人産業技術総合研究所 | α−マンノシダーゼ |
| JP4742191B2 (ja) | 2001-06-14 | 2011-08-10 | 独立行政法人産業技術総合研究所 | 糖蛋白質およびその製造方法 |
| ES2405551T3 (es) | 2001-10-01 | 2013-05-31 | Dyax Corporation | Vectores de presentación eucariotas multicatenarios y usos de los mismos |
| US7473680B2 (en) * | 2001-11-28 | 2009-01-06 | Neose Technologies, Inc. | Remodeling and glycoconjugation of peptides |
| KR101001243B1 (ko) | 2001-12-27 | 2010-12-17 | 글리코파이, 인크. | 포유동물-유형 탄수화물 구조의 설계 방법 |
| MXPA04009418A (es) | 2002-03-29 | 2005-06-08 | Schering Corp | Anticuerpos monoclonales humanos par interleucina-5, y metodos y composiciones que comprenden los mismos. |
| EP1505149B1 (en) | 2002-04-26 | 2009-01-07 | Kirin Pharma Kabushiki Kaisha | Methylotroph yeast producing mammalian type sugar chain |
| IL165717A0 (en) * | 2002-06-26 | 2006-01-15 | Flanders Interuniversity Inst | A strain of methylotrophic yeast for producing proteins |
| ATE480624T1 (de) | 2002-06-29 | 2010-09-15 | Korea Res Inst Of Bioscience | Yapsin-mangelmutantenstamm von hansenula polymorpha sowie verfahren zur herstellung rekombinanter proteine damit |
| KR100470978B1 (ko) | 2003-01-02 | 2005-03-10 | 한국생명공학연구원 | 앱신 다중 결손 효모 변이 균주 및 이를 이용한 재조합 단백질의 생산 방법 |
| AU2012206984B2 (en) | 2003-02-11 | 2015-07-09 | Takeda Pharmaceutical Company Limited | Diagnosis and treatment of multiple sulfatase deficiency and other using a formylglycine generating enzyme (FGE) |
| JP4259169B2 (ja) | 2003-04-16 | 2009-04-30 | 昭和産業株式会社 | 新規α−１，２−マンノシダーゼおよびその遺伝子、ならびに該酵素を用いたα−マンノシル糖化合物の製造方法 |
| US7259255B2 (en) | 2003-06-25 | 2007-08-21 | E. I. Du Pont De Nemours And Company | Glyceraldehyde-3-phosphate dehydrogenase and phosphoglycerate mutase promoters for gene expression in oleaginous yeast |
| EP2341128A1 (en) | 2003-12-24 | 2011-07-06 | GlycoFi, Inc. | Methods for eliminating mannosylphosphorylation of glycans in the production of glycoproteins |
| ES2344302T3 (es) | 2004-02-10 | 2010-08-24 | Zystor Therapeutics , Inc. | Alfa glucosidasa acida y fragmentos de la misma. |
| US20050265988A1 (en) | 2004-03-18 | 2005-12-01 | Byung-Kwon Choi | Glycosylated glucocerebrosidase expression in fungal hosts |
| AU2005233387B2 (en) | 2004-04-15 | 2011-05-26 | Glycofi, Inc. | Production of galactosylated glycoproteins in lower eukaryotes |
| CA2501422C (en) | 2004-04-29 | 2014-08-12 | University Of Rochester | Lymphoid chemokines in the diagnosis, monitoring and treatment of autoimmune disease |
| US7465577B2 (en) | 2004-04-29 | 2008-12-16 | Glycofi, Inc. | Methods for reducing or eliminating α-mannosidase resistant glycans for the production of glycoproteins |
| US20060014264A1 (en) | 2004-07-13 | 2006-01-19 | Stowers Institute For Medical Research | Cre/lox system with lox sites having an extended spacer region |
| US7431927B2 (en) | 2005-03-24 | 2008-10-07 | Epitomics, Inc. | TNFα-neutralizing antibodies |
| CA2604917A1 (en) | 2005-04-14 | 2007-01-25 | Csir | Recombinant yeasts for synthesizing epoxide hydrolases |
| CN101313216A (zh) | 2005-09-22 | 2008-11-26 | 普洛茨股份有限公司 | 酵母突变体中产生的糖基化多肽及其使用方法 |
| US20080081035A1 (en) | 2006-10-03 | 2008-04-03 | National Enzyme Company | Therapeutic protease compositions |
| WO2008100816A2 (en) | 2007-02-09 | 2008-08-21 | Medimmune, Llc | Antibody libray display by yeast cell plasma membrane |
| EP2508613A3 (en) * | 2007-04-03 | 2012-11-28 | Oxyrane UK Limited | Glycosylation of molecules |
| JP5507242B2 (ja) | 2007-05-18 | 2014-05-28 | 公益財団法人東京都医学総合研究所 | 酵素補充療法用医薬組成物 |
| US8825012B2 (en) * | 2007-09-14 | 2014-09-02 | Unwired Planet, Llc | User data notification in a mobile communications system |
| KR101744142B1 (ko) | 2008-01-18 | 2017-06-07 | 바이오마린 파머수티컬 인크. | 활성이고 높은 정도로 인산화된 인간 리소좀 술파타아제 효소의 제조 및 그 용도 |
| JP2011514157A (ja) * | 2008-02-20 | 2011-05-06 | グライコフィ， インコーポレイテッド | 蛋白質生産用ベクター及び酵母株 |
| US20110223147A1 (en) | 2008-05-07 | 2011-09-15 | Zystor Therapeutics, Inc. | Lysosomal targeting peptides and uses thereof |
| JP2012518999A (ja) | 2009-02-26 | 2012-08-23 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 宿主細胞およびその使用方法 |
| JP5990102B2 (ja) | 2009-09-29 | 2016-09-07 | ユニフェルシテイト ヘント | ホスホ−６−マンノースへのマンノース−１−ホスホ−６−マンノース結合の加水分解 |
| BR112012011980A2 (pt) | 2009-11-19 | 2021-09-08 | Oxyrane Uk Limited | Métodos de produzir células transformadas de yarrowia lipolytica e proteínas-alvocompreendendo n-glicanos, células transformadas de yarrowia lipolytica e suas culturas, bem como composição compreendendo glicoproteínas |
| FR2954349A1 (fr) | 2009-12-22 | 2011-06-24 | Agronomique Inst Nat Rech | Sulfatase modifiant selectivement les glycosaminoglycanes |
| WO2011089527A1 (en) | 2010-01-21 | 2011-07-28 | Oxyrane Uk Limited | Methods and compositions for displaying a poypeptide on a yeast cell surface |
| US20120135461A1 (en) | 2010-07-30 | 2012-05-31 | William James Cook | Production of glycoproteins with reduced o-glycosylation comprising the use of an alpha-1,2-mannosidase |
| CA2812870C (en) | 2010-09-29 | 2020-06-09 | Oxyrane Uk Limited | Mannosidases capable of uncapping mannose-1-phospho-6-mannose linkages and demannosylating phosphorylated n-glycans and methods of facilitating mammalian cellular uptake of glycoproteins |
| SG189110A1 (en) | 2010-09-29 | 2013-05-31 | Oxyrane Uk Ltd | De-mannosylation of phosphorylated n-glycans |
| SG11201403506TA (en) | 2011-12-30 | 2014-07-30 | Oxyrane Uk Ltd | Methods and materials for reducing degradation of recombinant proteins |
| CN104379162B (zh) | 2012-03-15 | 2017-03-15 | 奥克西雷恩英国有限公司 | 用于治疗蓬佩氏病的方法和材料 |
| EP2964758B1 (en) | 2013-03-05 | 2020-05-27 | Oxyrane UK Limited | Production of catalytically active type i sulfatase |
-
2010
- 2010-11-19 BR BR112012011980-0A patent/BR112012011980A2/pt not_active Application Discontinuation
- 2010-11-19 KR KR1020127015208A patent/KR20130055555A/ko not_active Withdrawn
- 2010-11-19 DK DK10812879.4T patent/DK2501805T3/en active
- 2010-11-19 US US13/510,527 patent/US20130053550A1/en not_active Abandoned
- 2010-11-19 JP JP2012539436A patent/JP2013511272A/ja active Pending
- 2010-11-19 EP EP10812879.4A patent/EP2501805B1/en active Active
- 2010-11-19 WO PCT/IB2010/003154 patent/WO2011061629A2/en not_active Ceased
- 2010-11-19 CN CN2010800618574A patent/CN102834509A/zh active Pending
- 2010-11-19 CA CA2781240A patent/CA2781240A1/en not_active Abandoned
-
2015
- 2015-03-06 US US14/641,002 patent/US10287557B2/en active Active
-
2019
- 2019-04-11 US US16/381,523 patent/US11225646B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011061629A3 (en) | 2011-12-01 |
| US20190233802A1 (en) | 2019-08-01 |
| US20150337273A1 (en) | 2015-11-26 |
| WO2011061629A2 (en) | 2011-05-26 |
| CN102834509A (zh) | 2012-12-19 |
| US20130053550A1 (en) | 2013-02-28 |
| DK2501805T3 (en) | 2019-04-15 |
| US10287557B2 (en) | 2019-05-14 |
| EP2501805A2 (en) | 2012-09-26 |
| KR20130055555A (ko) | 2013-05-28 |
| JP2013511272A (ja) | 2013-04-04 |
| CA2781240A1 (en) | 2011-05-26 |
| US11225646B2 (en) | 2022-01-18 |
| EP2501805B1 (en) | 2019-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012011980A2 (pt) | Métodos de produzir células transformadas de yarrowia lipolytica e proteínas-alvocompreendendo n-glicanos, células transformadas de yarrowia lipolytica e suas culturas, bem como composição compreendendo glicoproteínas | |
| Barone et al. | Industrial production of proteins with Pichia pastoris—Komagataella phaffii | |
| Krainer et al. | Knockout of an endogenous mannosyltransferase increases the homogeneity of glycoproteins produced in Pichia pastoris | |
| Damasceno et al. | Protein secretion in Pichia pastoris and advances in protein production | |
| Amann et al. | Genetic engineering approaches to improve posttranslational modification of biopharmaceuticals in different production platforms | |
| Rodriguez et al. | Enhanced production of monomeric interferon‐β by CHO cells through the control of culture conditions | |
| Hamilton et al. | Production of sialylated O-linked glycans in Pichia pastoris | |
| Kildegaard et al. | Glycoprofiling effects of media additives on IgG produced by CHO cells in fed‐batch bioreactors | |
| Kerkhoven et al. | Applications of computational modeling in metabolic engineering of yeast | |
| CN101679934B (zh) | 具有经修饰的岩藻糖基化的糖蛋白的生产 | |
| JP2013511272A5 (enExample) | ||
| AU2011247333A1 (en) | Improved glycosylation of proteins in host cells | |
| Kommineni et al. | In vivo glycan engineering via the mannosidase I inhibitor (Kifunensine) improves efficacy of rituximab manufactured in Nicotiana benthamiana plants | |
| Yu et al. | Improving the secretory production of the heterologous protein in Pichia pastoris by focusing on protein folding | |
| AU2009309925A1 (en) | Novel tools for the production of glycosylated proteins in host cells | |
| Katla et al. | Novel glycosylated human interferon alpha 2b expressed in glycoengineered Pichia pastoris and its biological activity: N-linked glycoengineering approach | |
| MX2012004994A (es) | Metodo para producir proteinas terapeuticas en pichia pastoris que carecen de actividad de dipeptidil aminopeptidasa. | |
| Piirainen et al. | A dual approach for improving homogeneity of a human-type N-glycan structure in Saccharomyces cerevisiae | |
| JP2014532406A (ja) | 組換えタンパク質発現のための操作された下等真核宿主株 | |
| CN102482674B (zh) | 制备具有高唾液酸含量的重组糖蛋白的方法 | |
| Ingram et al. | Overcoming obstacles in protein expression in the yeast Pichia pastoris: interviews of leaders in the pichia field | |
| CN104736694B (zh) | Crz1突变型真菌细胞 | |
| Sam et al. | Enhancement of glycosylation by stable co-expression of two sialylation-related enzymes on Chinese hamster ovary cells | |
| Bosco et al. | Alternating flow filtration as an alternative to internal spin filter based perfusion process: Impact on productivity and product quality | |
| CA2827732A1 (en) | Yeast strain for the production of proteins with modified o-glycosylation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B25G | Requested change of headquarter approved |
Owner name: OXYRANE UK LIMITED (GB) |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |